Genentech Articles
US pulmonologists view refractory asthma patient treatment with biosimilar Xolair by end-2018
10 April 2013
Pharmaco-invasive strategy including Metalyse comparable to primary PCI for STEMI patients
11 March 2013
Genentech Ph III study of omalizumab shows promise in CIU
25 February 2013
US FDA approves Roche's late-stage breast cancer drug Kadcyla
25 February 2013
Genentech enters $111 million drug discovery pact with RQx Pharma
13 February 2013
US biotech giants lobbying to block biosimilars, NTY claims
31 January 2013
Roche affiliate Chugai files for T-DM1 approval in Japan; gains rights to Afraxis compound
30 January 2013
FDA clears new use for Roche's Avastin and Novartis' Exjade
25 January 2013
San Antonio breast cancer meeting highlights
10 December 2012
Curis in-licenses cancer candidate from Genentech
30 November 2012
US oncologists' perceptions of Roche's Perjeta very promising
7 September 2012
Genentech's T-DM1 significantly improved survival for metastatic breast cancer patients
29 August 2012
GSK settles with Genentech over ofatumumab patents
28 March 2012
Counterfeit Avastin found in USA by FDA
16 February 2012
Faster-than-expected FDA approval of Roche’s vismodegib
31 January 2012
Roche in epigenetics drug discovery collaboration
18 January 2012
Xenon in $646 million deal with Roche unit
10 January 2012
Vernalis jumps on deal with Genentech
5 January 2012
Roche unit in partial patent deal with Regeneron over Eylea; new indication for Avastin
4 January 2012
US court rules in GlaxoSmithKline’s favor in Arzerra patent dispute
18 November 2011
FDA priority review for Roche/Genentech’s vismodegib for skin cancer
10 November 2011
Gilead gains US approval for Complera, resolves manufacturing problem and buys Genentech facility
11 August 2011
US Nevada state judge denies Roche and Genentech motions to dismiss PDL BioPharma's royalties complaint
12 July 2011
Second Lucentis Ph III study meets primary endpoint for improved vision in DME patients
28 March 2011
US FDA allows Genentech/Roche to present case for Avastin in metastatic breast cancer
25 February 2011
Roche gets US FDA approval for Rituxan for follicular lymphoma maintenance; Tarceva meets primary endpoint
31 January 2011
Roche/Genentech appeal FDA decision on Avastin for breast cancer; positive results with melanoma drug
19 January 2011
US FDA to halt breast cancer use for Roche’s Avastin, but EMA says it’s OK in combo with paclitaxel; no immediate somatropin concerns
17 December 2010
EMA advised Pfizer is withdrawing Thelin due to serious liver damage; starts somatropin drugs review
13 December 2010
Pfizer’s tasocitinib reduced signs and symptoms of rheumatoid arthritis in Ph III study; New data on Roche’s Actemra in RA
8 November 2010
US FDA approves Genentech/Roche’s Herceptin for HER2-positive metastatic stomach cancer; Roche amends deal with Biogen
22 October 2010
GlaxoSmithKline sues Roche/Genentech alleging Herceptin patent infringements; updates on Relovair Ph II development with Theravance
23 September 2010
PDL BioPharma sues Roche’s Genentech over royalties
2 September 2010
Roche tells Curis that Ph II data on GDC-0449 in advanced ovarian cancer needs additional investigation
10 August 2010
Genentech and Seattle Genetics expand collaboration; Genzyme/Isis cholesterol candidate meets Ph III goals
5 August 2010
Roche’s Genentech buys rights to NovImmune’s MAb
27 July 2010
Big blow for Roche, as US FDA advisory panel votes to withdraw Avastin approval for breast cancer treatment
21 July 2010
Curis shares plummet as “Hedgehog” drug being developed with Roche fails in colorectal cancer trial
17 June 2010
Human Genome/GlaxoSmithKline lupus drug Benlysta disappoints in Ph III; Updates on Seattle Genetics and Ligand milestones
21 April 2010
OSI/Genentech gain additional indication from US FDA for Tarceva as maintenance therapy for advanced NSCLC
19 April 2010
Icahn seeks to influence Genzyme, nominating four board directors
23 February 2010
US FDA warns on renal, hepatic and gastro problems with Novartis’ Exjade; clears Roche/Biogen’s Rituxan for CLL
19 February 2010
Targeted cancer drug market set to reach $51 billion by 2015, led by Pfizer; barriers to use of oral cancer drugs identified
19 February 2010
Curis and Bioniche each get $8 million milestones in respective deals with Debiopharm and Endo
15 February 2010
Burst of M&A activity in pharma during 2009 led by mega-deals from Pfizer/Wyeth and Merck & Co/S-P
4 February 2010
Pharmaceutical M&A deals in 2009
4 February 2010
Roche 2009 figures miss targets, hit by Genentech buy costs and slowing sales of some cancer drugs
3 February 2010
FDA delays approval of OSI/Genentech/Roche’s Tarceva for advanced non-small cell lung cancer
18 January 2010
FDA finally approves Roche’s Actemra for moderately-to-severely active rheumatoid arthritis
11 January 2010
Roche/Genentech pull out of dacetuzumab deal with Seattle Genetics
14 December 2009
Ischemic stroke continues to be a graveyard for drug development, says Decision Resources, but market will grow to $450 million in 2018
18 November 2009
Seattle Genetics hires new commercial chief, promotes legal exec
14 October 2009
Seattle Genetics slumps on stopping dacetuzumab Phase IIb diffuse large B-cell lymphoma trial
6 October 2009
Roche announces senior management changes
8 September 2009
Rituxan submitted to FDA for new CLL uses
28 May 2009
Pfizer to raise $10.6B to finance Wyeth buy
28 May 2009
Stock Commentary - New York week to May 18, 2009
21 May 2009
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- Elan makes "transformational" acquisitions and a divestment
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- CIS countries prepare for the introduction of drug reimbursement schemes
- Greek research-based drugmaker group AIFD challenges generics assumptions in Draft Patent Law
